All In Biotech

Drug Trial Radar · NCT03630315

CLN-0046: Treatment of AMD Subjects With OTX-TKI

A Phase 1 Open-Label, Dose Escalation Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Feb 18, 2019

Primary completion

Jan 10, 2024

Study completion Jan 10, 2024

Sponsor

Lead sponsor
Ocular Therapeutix, Inc.Industry
Sponsor type
Industry
First posted
Aug 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability and efficacy of OTX-TKI for intravitreal use, in subjects who have neovascular age-related macular degeneration (AMD).

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • OTX-TKIDrug

    OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

  • OTX-TKIDrug

    OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

  • OTX-TKIDrug

    OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

  • OTX-TKIDrug

    OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

  • Anti-VEGFDrug

    Standard of care therapy used to block vascular endothelial growth factor

  • OTX-TKIDrug

    OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

  • Anti-VEGFDrug

    Standard of care therapy used to block vascular endothelial growth factor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent adverse events for each subjectTime frame: 9 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Ocular Therapeutix, Inc.

    Adelaide, Australia

  • Ocular Therapeutix, Inc.

    Albury, Australia

  • Ocular Therapeutix, Inc.

    Melbourne, Australia

  • Ocular Therapeutix, Inc.

    Sydney, Site 1, Australia

  • Ocular Therapeutiux, Inc.

    Sydney, Site 2, Australia

  • Ocular Therapeutiux, Inc.

    Sydney, Site 3, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.